Isatuximab for multiple myeloma – promising results and next steps

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of monoclonal antibody therapy in multiple myeloma (MM). Daratumumab and elotuzumab are already approved and according to Prof Martin, the next monoclonal antibody to be approved will be isatuximab. Isatuximab like daratumumab, targets CD38 and responses to the drug in pre-clinical work and clinical trials have been good. In the initial Phase I trial in relapsed/refractory myeloma (NCT01749969), the response rate to isatuximab was over 30% and in combination with lenalidomide and dexamethasone, the response rate was in the 60% range. Prof Martin further discusses preliminary data on combining isatuximab with carfilzomib, which showed a response rate of 77%. According to Prof Martin, it is now time for the Phase III studies of isatuximab.
Recorded at the Myeloma 2016 meeting held in Boston, MA.

Share this video